Central News Agency (CNA, reporter Chen Jie-ling, Taipei, July 1) Early-stage lung cancer is prone to recurrence even after surgery. Over half of lung adenocarcinoma patients in Taiwan have gene mutations associated with a higher risk of recurrence and metastasis. Medical groups pointed out today that post-operative targeted adjuvant therapy can reduce recurrence risk by 80%, urging its prompt inclusion in National Health Insurance coverage. Chang Chia-lun, Vice Executive Director of the Taiwan Cancer Foundation and Director of the Department of Hematology-Oncology at Taipei City Wanfang Hospital, stated at a press conference today that cancer has been the leading cause of death for the nation for 44 consecutive years, and lung cancer has been the top killer for 22 consecutive years. One out of every five cancer deaths in the country is attributed to lung cancer. With its high incidence rate, lung cancer has always been a top priority in Taiwan's cancer prevention and control efforts. The Ministry of Health and Welfare's Health Promotion Administration has been providing free low-dose computed tomography (LDCT) screening for high-risk groups for lung cancer since July 1, 111 (2022). Chang Chia-lun said that in the four years since its implementation, 3,139 confirmed lung cancer cases have been identified, with over 80% being early-stage. The budgets for early cancer screening and the NT$10 billion cancer new drug fund are gradually in place. The next step should be to improve patients' accessibility to medications aligned with international guidelines. Post-operative targeted adjuvant therapy for early-stage lung cancer (Stage 1B to 3A) to reduce recurrence has become an international standard guideline. Wang Chin-chou, Vice Superintendent of Kaohsiung Chang Gung Memorial Hospital, said that early-stage lung cancer accounts for 65% of cases in Taiwan. The increase in early-stage lung cancer detection has driven a rise in demand for early treatment. The more troubles